Search

Your search keyword '"Robb, Merlin"' showing total 1,500 results

Search Constraints

Start Over You searched for: Author "Robb, Merlin" Remove constraint Author: "Robb, Merlin"
1,500 results on '"Robb, Merlin"'

Search Results

1. The Association Between Heterosexual anal Intercourse and HIV Acquisition in Three Prospective Cohorts of Women

2. Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapy

3. Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials

4. Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption

5. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

6. Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine

7. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine

8. Tracking coreceptor switch of the transmitted/founder HIV-1 identifies co-evolution of HIV-1 antigenicity, coreceptor usage and CD4 subset targeting: the RV217 acute infection cohort study

9. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

10. Risk of COVID-19 after natural infection or vaccination

11. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study

12. Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial

13. Initial productive and latent HIV infections originate in vivo by infection of resting T cells

14. Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes

16. Multiple HPV infections among men who have sex with men engaged in anal cancer screening in Abuja, Nigeria

17. Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection.

18. Liver function test abnormalities in a longitudinal cohort of Thai individuals treated since acute HIV infection

19. Very Early Initiation of Antiretroviral Therapy During Acute HIV Infection Is Associated With Normalized Levels of Immune Activation Markers in Cerebrospinal Fluid but Not in Plasma

20. Preferential and persistent impact of acute HIV-1 infection on CD4⁺ iNKT cells in colonic mucosa

22. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

23. Determinants of Preexposure Prophylaxis Cascade Among Sexual and Gender Minorities in Nigeria

24. SARS-CoV-2 recombinant spike ferritin nanoparticle vaccine adjuvanted with Army Liposome Formulation containing monophosphoryl lipid A and QS-21: a phase 1, randomised, double-blind, placebo-controlled, first-in-human clinical trial

25. Author response: A remarkable genetic shift in a transmitted/founder virus broadens antibody responses against HIV-1

26. A remarkable genetic shift in a transmitted/founder virus broadens antibody responses against HIV-1

27. Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting

28. Acute HIV-1 infection viremia associate with rebound upon treatment interruption

29. Dissecting drivers of immune activation in chronic HIV-1 infection

30. Brain volumetrics differ by Fiebig stage in acute HIV infection

31. Therapeutic efficacy of an Ad26/MVA vaccine with SIV gp140 protein and vesatolimod in ART-suppressed rhesus macaques

32. Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques

34. The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination

35. Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease.

36. Computational analysis of antibody dynamics identifies recent HIV-1 infection

37. Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection

38. Author Response: A Remarkable Genetic Shift in a Transmitted/Founder Virus Broadens Antibody Responses Against HIV-1

39. Risk Factors for HIV sero-conversion in a high incidence cohort of men who have sex with men and transgender women in Bangkok, Thailand

40. Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults

41. Preservation of Peripheral T Follicular Helper Cell Function in HIV Controllers

42. T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response

44. Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study

45. Safety and Immunogenicity of an Accelerated Ebola Vaccination Schedule in People with and without Human Immunodeficiency Virus: A Randomized Clinical Trial.

46. Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial

47. Retention of a cohort of men who have sex with men and transgender women at risk for and living with HIV in Abuja and Lagos, Nigeria: a longitudinal analysis

48. High frequency of HIV precursor-target-specific B cells in sub-Saharan populations

49. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial

50. Efficacy of a monovalent (D614) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, multi-country study

Catalog

Books, media, physical & digital resources